Tag: Asthma

Posted on

Study on the Treatment of Bronchial Asthma With Traditional Chinese Medicine

Condition:   Bronchial Asthma
Interventions:   Drug: Ke Chuan Liu Wei Mixture;   Drug: Chuan Xiong Ping Chuan Mixture;   Drug: Xie Wu Capsule;   Drug: Dan Ma Jia Tablet;   Drug: Zhi Chuan Capsule;   Drug: Bu Shen Na Qi Granule;   Drug: Ke Chuan Liu Wei Mixture placebo;   Drug: Chuan Xiong Ping Chuan Mixture placebo;   Drug: Xie Wu Capsule placebo;   Drug: Dan Ma Jia Tablet placebo;   Drug: Zhi Chuan Capsule placebo;   Drug: Bu Shen Na Qi Granule placebo
Sponsor:   Shanghai University of Traditional Chinese Medicine
Not yet recruiting – verified October 2016

View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days

Posted on

A 12-week, Randomized, Parallel-Group, Proof-of-Concept Study of Tulobuterol Patch and Salmeterol Inhaler as Add-on Therapy in Adult-Onset Mild-to-Moderate Asthma.

Related Articles

A 12-week, Randomized, Parallel-Group, Proof-of-Concept Study of Tulobuterol Patch and Salmeterol Inhaler as Add-on Therapy in Adult-Onset Mild-to-Moderate Asthma.

Clin Exp Pharmacol Physiol. 2016 Oct 8;:

Authors: Inoue H, Niimi A, Matsumoto H, Ito I, Oguma T, Otsuka K, Takeda T, Nakaji H, Tajiri T, Iwata T, Nagasaki T, Mishima M

Abstract
Patch formulation of tulobuterol has been used in asthma treatment as a long-acting ?2 -agonist (LABA) through sustained skin absorption. Its treatment efficacy, especially in small airways, remains poorly understood. The study aim was to investigate LABA add-on effects of tulobuterol patch (TP) and salmeterol inhaler (SA) on pulmonary function, asthma control, and health status. Patients who had adult-onset under-controlled asthma, despite taking inhaled corticosteroids, were enrolled in a randomized, open-label, parallel-group, proof-of-concept study of 12-week add-on treatment with TP (n = 16) or SA (n = 17). Spirometry, impulse oscillometry (IOS), exhaled nitric oxide levels, and clinical questionnaires of asthma control, health status (St. George’s Respiratory Questionnaire: SGRQ), and symptoms were evaluated every 4 weeks. Add-on treatment of SA significantly improved the spirometric indices of small airway obstruction (forced expiratory flow between 25% and 75% of FVC: FEF25-75 , and maximum expiratory flow at 25% of FVC: MEF25 ) and IOS indices of whole respiratory resistance (resistance at 5 Hz) as compared to TP. In intra-group comparisons, add-on treatment of TP improved the scores of the asthma control test and the total SGRQ, as well as the symptom and impact components of the SGRQ. SA add-on treatment improved FEV1 and IOS parameters of resistance at 20 Hz and reactance at 5 Hz. Neither of the treatments improved exhaled nitric oxide levels. In conclusion, add-on treatment of TP improved asthma control and health status, whereas SA improved pulmonary function measures associated with large and small airway involvement among patients with adult-onset mild-to-moderate asthma. This article is protected by copyright. All rights reserved.

PMID: 27718262 [PubMed – as supplied by publisher]

View full post on pubmed: asthma